Univ. of Minnesota Results of notable clinical studies post-exposure (-) French case report study (+) China study RCT (-) VA Study Australia HCP ACTT (+: 15 vs. 11 real-world study (-) Hydroxy- prophylaxis (ongoing) days inpatient and chloroquine WHO SOLIDARITY mortality trend) study (ongoing) Remdesivir IL-6 inhibitor Leronlimab (+) Case reports (+) IL=-6 inhibitor >600 Tocilzumab (+/-) ongoing Supportive IL-6 inhibitor clinical therapies Sarilumab (-) studies China case-reports (+) Anticoagulation (+) Key NYU series (+) Convalescent + in combination plasma with ribavirin and = demonstrates positive benefit Lopinavir/ interferon 1b = negative effect or outcome ritonavir = neutral or ongoing study US safety studies (+) WHO SOLIDARITY (-) vs. standard study with and without of care Source: https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker interferon (ongoing) IQVIA Global Executive Briefing: COVID-19 June 2020; Copyright 2020 IQVIA. 13